This case-based enduring activity will cover the diagnosis, treatment and management of patients with severe asthma.

Idiopathic pulmonary fibrosis (IPF) is considered the classic presentation of the fibrotic interstitial lung diseases (ILDs).

Progressive fibrosing-interstitial lung disease (PF-ILD) comprises serious pulmonary disorders that have a significant impact on the quality of life of affected patients, with considerable morbidity and mortality.

his CME activity reviews how to utilize available clinical guidelines to accurately diagnose patients with severe asthma vs difficult-to-treat asthma and how to utilize strategies to minimize the use of OCS in patients with severe asthma in order to reduce OCS-related adverse effects and improve quality of life.

This activity series presents the common challenges of diagnosing and managing progressive fibrotic interstitial lung disease subtypes of IPF and SSc-ILD . There is at present no cure for IPF or SSc-ILD and existing treatments focus on delaying disease progression, controlling symptoms and preventing complications.